Drug Trial Radar · NCT06804096
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Feb 20, 2025
Primary completion
Jan 12, 2026
Study completion Jan 26, 2026
Sponsor
- Lead sponsor
- Dr. Md. Alimur RezaIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.
Conditions
- Pneumonia, Community-Acquired
- Bacterial Pneumonia
Interventions
FaropenemDrug
Tab. Faropenem 200mg three times daily
Co-amoxiclavDrug
Tab. Co-Amoxiclav 625mg three times daily
Clarithromycin 500 mgDrug
Tab. Clarithromycin 500mg two times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Cure Rate between two groups.Time frame: 10-14 days
- Percentage of patients withdrawn from the study due to adverse events between two groups.Time frame: 10-14 Days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Popular Medical College & Hospital
Dhaka, Dhaka Division, Bangladesh
Shaheed Suhrawardy Medical College & Hospital
Dhaka, Dhaka Division, Bangladesh
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.